Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer
Compounds that are fatty acid synthesis modulators are provided. The compounds may be used in pharmaceutical compositions to treat taxane-resistant cancers. Methods are provided for treating taxane-resistant cancer in a subject. Methods are also provided for increasing the sensitivity of a cancer cell to taxanes (i.e., paclitaxel, Nab-paclitaxel docetaxel, and/or cabazitaxel) treatment.
1. A method of treating a taxane-resistant tumor or cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of:
(i) a fatty acid synthase inhibitor having the structure of:
and
(ii) a taxane.
2. The method of claim 1 wherein the taxane-resistant cancer is lung cancer.
3. The method of claim 1 wherein the taxane-resistant cancer is breast cancer.
4. The method of claim 1 wherein the taxane-resistant cancer is ovarian cancer.
5. The method of claim 1 wherein the taxane-resistant cancer is prostate cancer.
6. The method of claim 1 wherein the taxane-resistant cancer is colon cancer.
7. The method of claim 1 wherein the taxane-resistant cancer is pancreatic cancer.
8. The method of claim 1 wherein the fatty acid synthase inhibitor is administered simultaneously with the taxane.
9. The method of claim 8 wherein the fatty acid synthase inhibitor and the taxane are administered simultaneously as a single pharmaceutical composition.
10. The method of claim 8 wherein the fatty acid synthase inhibitor and the taxane are administered simultaneously as separate dosage forms.
11. The method of claim 1 wherein the fatty acid synthase inhibitor is administered before the taxane is administered.
12. The method of claim 1 wherein the fatty acid synthase inhibitor is administered after the taxane is administered.
13. The method of claim 1 , wherein the taxane-resistant tumor is resistant to paclitaxel.
14. The method of claim 1 , wherein the taxane-resistant tumor is resistant to Nab-paclitaxel.
15. The method of claim 1 , wherein the taxane is paclitaxel.
16. The method of claim 1 , wherein the taxane is Nab-paclitaxel.
17. The method of claim 1 , wherein the taxane is docetaxel.
18. The method of claim 1 , wherein the taxane is cabazitaxel.
19. The method of claim 1 , wherein the taxane-resistant tumor is resistant to cabazitaxel.
20. The method of claim 1 , wherein the taxane-resistant tumor is resistant to docetaxel.